Isodiol International Inc. Provides Update on Be Tru Organics, Announces New Distribution Agreement

Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce Be Trū Organics™ has signed a distribution agreement with United Natural Foods Inc (UNFI), the largest publicly traded wholesale distributor to the natural, organic and specialty industry in the United States and Canada.
With their distribution centers in the US and Canada, UNFI excels in the distribution of natural and organic foods and wellness products by fulfilling the highest standards for quality, consistency, product assortments, and dependability. Specifically, UNFI provides and delivers products for grocery, produce, health and beauty, bakery, and more.
“UNFI been recognized as one of America’s best managed companies, and with the continuous growth in the natural product industry, we are very excited about the opportunities this presents for Be Trū,” said CEO of Isodiol, Marcos Agramont. “UNFI has a very diversified sales base including natural product superstores, conventional supermarket chains, and independent health food retailers, giving consumers plenty of access to Be Trū products.”
“UNFI’s track record speaks for itself, and we are very pleased to be moving forward with this distribution agreement,” added Keith Gordon, CEO of Be Trū. “UNFI will be instrumental in introducing this brand to mainstream America and will allow Be Trū to continue growing and we look forward to the additional opportunities this agreement will present.”
For more information on Isodiol, please visit www.isodiol.com
For more information on Be Trū Organics™, please visit www.betruorganics.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
Forward-Looking Information:This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
Click here to connect with Isodiol International Inc. (CSE:ISOL) to receive an Investor Presentation

Source: globenewswire.com